Significance of L-carnitine in internal medicine

被引：7
作者：
Sizova, Zh M. [1 ]
Shikh, E., V [1 ]
Makhova, A. A. [1 ]
机构：
[1] IM Sechenov First Moscow State Med Univ, Sechenov Univ, Minist Hlth Russian Federat, Moscow, Russia
来源：
TERAPEVTICHESKII ARKHIV | 2019年 / 91卷 / 01期
关键词：
L-carnitine; P450; CYP; 3A4; chronic heart failure; myocardial infarction; chronic renal failure; inter-drug interaction; antioxidant; antihypoxant; ACETYL-L-CARNITINE; STAGE RENAL-DISEASE; MYOCARDIAL-INFARCTION; HEMODIALYSIS-PATIENTS; EXERCISE TOLERANCE; STABLE ANGINA; OLD RATS; SUPPLEMENTATION; DEFICIENCY; THERAPY;
D O I：
10.26442/00403660.2019.01.000040
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
The review presents the results of a number of experimental and clinical studies proving the prospects of using L-carnitine in the clinic of internal diseases. Due to the antioxidant and antihypoxant properties, the additional use of L-carnitine in addition to the main etiopathogenetic therapy is prescribed by cardiologists, nephrologists, neurologists, gerontologists. Experimental studies we conducted earlier showed no effect of L-carnitine on the activity of the P450 CYP 3A4 system, which reduces the likelihood of drug-drug interaction at the level of metabolism of drugs metabolized by P450 3A4. When using L-carnitine as part of complex pharmacotherapy, the drug has an increased safety profile in comorbid patients taking L-carnitine.
引用
收藏
页码：114 / 120
页数：7
相关论文
共 53 条
  • [1] [Anonymous], 2000, VITAMIN C DIETARY RE, P95
  • [2] [Anonymous], 2017, BIOMED RES INT, DOI [DOI 10.1155/2017/6274854, 10.1155/2017/6274854]
  • [3] [Асташкин Е.И. Astashkin E.I.], 2016, [Кардиоваскулярная терапия и профилактика, Cardiovascular Therapy and Prevention, Kardiovaskulyarnaya terapiya i profilaktika], V15, P28
  • [4] Astashkin E.I., 2016, MED COUNCIL, V10, P94
  • [5] Astashkin E.I., 2012, CARDIOLOGY CARDIOVAS, V6, P58
  • [6] Parenteral iron use in the management of anemia in end-stage renal disease patients
    Bailie, GR
    Johnson, CA
    Mason, NA
    [J]. AMERICAN JOURNAL OF KIDNEY DISEASES, 2000, 35 (01) : 1 - 12
  • [7] Bodikhov MK, 2011, BREAST CANC NEUROLOG, V11, P3
  • [8] CACCIATORE L, 1991, DRUG EXP CLIN RES, V17, P225
  • [9] Carnitine replacement in end-stage renal disease and hemodialysis
    Calvani, M
    Benatti, P
    Mancinelli, A
    D'Iddio, S
    Giordano, V
    Koverech, A
    Amato, A
    Brass, EP
    [J]. CARNITINE: THE SCIENCE BEHIND A CONDITIONALLY ESSENTIAL NUTRIENT, 2004, 1033 : 52 - 66
  • [10] CHERCHI A, 1985, INT J CLIN PHARM TH, V23, P569
123456